Next-Generation Nanobody Therapy Targeting ALB and PDCD1 for Cancer Immunomodulation

VHH-P709 is a humanized nanobody program specifically engineered to target albumin (ALB) and programmed cell death 1 (PDCD1). Currently in the Biological Testing development stage, VHH-P709 holds significant promise for the treatment of cancer. The dual-target strategy leverages ALB’s plasma half-life extension properties and harnesses the immunomodulatory effects of PDCD1 blockades. This innovative construct may address limitations in current cancer therapies by combining extended systemic exposure with immune checkpoint inhibition, representing a novel approach to enhancing therapeutic efficacy.

Licensing Opportunity

VHH-P709 is available for out-licensing opportunities. We welcome inquiries from partners seeking to collaborate in the development and commercialization of innovative immuno-oncology nanobody therapeutics.

Development Phase

Modality

VHH-P709 is designed as a half-life extended, multivalent immunoglobulin single variable domain (ISVD) agent. The modality utilizes the small, stable single-domain antibody structure of nanobodies, enabling superior tissue penetration and target access compared to conventional antibodies. By fusing an ISVD targeting human PDCD1 with one targeting ALB via a flexible 35 GS linker, VHH-P709 achieves both immune checkpoint inhibition and prolonged circulatory stability. These structural advantages support enhanced tumor tissue accessibility and improved pharmacokinetics, making the modality highly relevant for cancer treatment where deep tissue infiltration and sustained activity are crucial.

Target

ALB and PDCD1 are central to VHH-P709’s mechanism. ALB functions as a major serum protein responsible for maintaining oncotic pressure and serves as an effective half-life extension vehicle for therapeutics. PDCD1 is an immune checkpoint receptor predominantly expressed on T cells and modulates immune responses to prevent autoimmunity. Overexpression of PDCD1 is frequently observed in the tumor microenvironment, contributing to immune evasion by cancer cells. Targeting ALB ensures retained therapeutic presence in circulation, while modulation of PDCD1 can unleash anti-tumor immunity. The strategic dual targeting of ALB and PDCD1 offers differentiated value in cancer therapy by promoting both prolonged exposure and robust immune activation, underscoring VHH-P709's potential to advance oncologic treatment.

Mechanism of Action

VHH-P709 exerts its therapeutic effect by simultaneously engaging ALB and PDCD1. As an anti-ALB and anti-PDCD1 nanobody, it binds to ALB, which prolongs its plasma half-life, ensuring sustained therapeutic exposure. By targeting PDCD1, VHH-P709 acts as an immune checkpoint inhibitor, blocking the interaction between PDCD1 and its ligands to restore T cell activity and enhance anti-tumor responses. The nanobody format enables modular development, supporting derivation into advanced therapeutic modalities such as antibody-drug conjugates (ADC) or bispecific constructs. This mechanism not only bolsters immune activation against cancer cells but also provides structural flexibility for future therapeutic innovations.

Cancer

Cancer remains one of the most prevalent and deadly diseases worldwide, characterized by the uncontrolled growth and spread of abnormal cells. It encompasses a broad spectrum of malignancies, each with distinct genetic and clinical features. Global epidemiological studies underscore the significant burden of cancer, with rising incidence and mortality rates in many regions. Current standard treatments include surgery, chemotherapy, radiation, targeted therapies, and immunotherapies. Despite progress, many patients experience relapse, limited response, or significant side effects from established interventions. Immunotherapy, particularly immune checkpoint blockade, has transformed outcomes for certain cancers but is not universally effective and can lead to immune-related adverse events. There is a pressing unmet need for therapies that provide durable responses, better safety profiles, and can overcome tumor immune evasion. VHH-P709, with its combined ALB-mediated pharmacokinetic enhancement and PDCD1 immune checkpoint inhibition, may address critical gaps—offering improved exposure, potent immunomodulation, and flexible applicability across multiple cancer types.